FDA Approves Mirdametinib in Adult/Pediatric NF1-PN Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

This offers a new hope for many patients and families.
Learn more: bit.ly/411tySo

Rare Cancers Program 2025 Coming Soon!

#NF1 #Neurofibromatosis #FDA #Mirdametinib #Gomekli #raredisease